ID
45559
Descrição
Principal Investigator: MeSH: Schizophrenia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000687 The primary aim of this study is to whole exome sequence complete Bulgarian trios to identify de novo mutations in schizophrenic probands. We are investigating the rate of de novo mutations in probands as well as looking for enrichment among previously implicated genes and synaptic gene sets.
Link
Palavras-chave
Versões (1)
- 10/01/2023 10/01/2023 - Simon Heim
Titular dos direitos
dbGAP
Transferido a
10 de janeiro de 2023
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs000687 Bulgarian Schizophrenia Trio Sequencing Study
Family ID, subject ID, father ID, mother ID, and sex of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Family ID, subject ID, father ID, mother ID, and sex of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Subject ID, sex, primary disease, analysis category, site where sequencing occurred, and samples meeting 80% of targets at 20X coverage, and obtained from participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Sample ID, body site where sample was obtained, analyte type, histological type of sample, and tumor status of sample associated with participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
Similar models
Family ID, subject ID, father ID, mother ID, and sex of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Family ID, subject ID, father ID, mother ID, and sex of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable of participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Subject ID, sex, primary disease, analysis category, site where sequencing occurred, and samples meeting 80% of targets at 20X coverage, and obtained from participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
- Sample ID, body site where sample was obtained, analyte type, histological type of sample, and tumor status of sample associated with participants with or without schizophrenia and involved in the "Bulgarian Trio Sequencing Study to Identify de Novo Mutations in Schizophrenia" project.
C0030761 (UMLS CUI [1,2])
C0030761 (UMLS CUI [1,2])
Sem comentários